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Electrophysiologic Mechanism of Conversion of Atrial Fibrillation
to Sinus Rhythm
KAZUO MOROE, TADAYUKI HIROKI, KEI MIYOSHI, TETSUSHI WAKIYAMA, RYUICHIRO MIYAWAKI,
YOSHIO URABE
From Chikushi Hospital, Fukuoka University, Fukuoka, Japan

MOROE, ET AL: Electrophysiologic Mechanism of Conversion of Atrial Fibrillation to Sinus Rhythm. We
investigated the validity of the circulating wavelet hypothesis as an explanation of the mechanism of termination of
atrial fibrillation in 11 patients with atrial fibrillation. During the atrial fibrillation, 11 electrocardiograms of the
right atrium and a left atrial electrocardiogram were recorded. The average interval of atrial potentials and the
standard deviation of the intervals at 12 atrial sites, defined as the dispersion of the interval during atrial fibrillation,
were determined. Pilsicainide resulted in successful conversion to sinus rhythm in 6 of 11 patients. Pilsicainide
significantly reduced the dispersion of the interval in responders compared with non-responders. The minimal
dispersion was observed just before termination of atrial fibrillation. These results suggest that the mechanism of
pharmacologic conversion of atrial fibrillation to sinus rhythm may be related to a decrease in the dispersion of
atrial fibrillation leading to synchronization of multiple reentrant wavelets in both atria. (J HK Coll Cardiol 1999;
7:87-95)
atrial fibrillation, termination, antiarrhythmic agent, mechanism, synchronization

Introduction
Atrial fibrillation, the most common symptom
in sustained and non-sustained arrhythmia, occurs in
2% of the general population.1 While its mechanisms
have not been fully clarified in humans, the reentrant
mechanism is generally accepted as an explanation
of the development and maintenance of atrial
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fibrillation. 2-4 Atrial fibrillation often terminates
spontaneously 5 and can be terminated by the
administration of antiarrhythmic drugs;1 the mechanism
of such termination is poorly understood. The
circulating wavelet hypothesis suggests that atrial
fibrillation is terminated by either the progressive fusion
or the simultaneous blockade of all wavelets. We
investigated the electrophysiologic effects of
pilsicainide, a new class 1C antiarrhythmic drug on the
conversion of atrial fibrillation to clarify the mechanism
of termination.

Methods
Patient characteristics
We studied 11 consecutive patients with
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paroxysmal atrial fibrillation who were undergoing
electrophysiologic studies at Chikushi Hospital of
Fukuoka University (7 men and 4 women, meam age:
64 ± 16 yr, range: 37 to 83 yr). The duration of atrial
fibrillation was less than 6 months in all patients.
Thyroid function was normal in all subjects. This
investigation conformed with the priciples outlined in
the Declaration of Helsinki. The study protocol was
approved by the Fukuoka University Committee on
Human Studies. Informed consent was obtained from
all subjects.

Electrophysiologic studies
Electrophysiologic studies were performed
during the spontaneous development of atrial fibrillation
following the discontinuation of antiarrhythmic drugs
for a period equal to 5 half-lives of the drug. Quadripolar
electrode catheters (6 Fr) positioned at the high right
atrium, at the right ventricular apex, in the coronary
sinus, and across the tricuspid valve, were used to record
intracardiac electrograms and for pacing. A deflectable
7-Fr Halo catheter (20 paired ring electrodes, HD-720P10-MS, Webster, Watertown, MA, USA) with 10mm spaces between pairs and 1-mm interelectrode
spacing was positioned on the annulus of the tricuspid
valve to record right atrial electrograms. The catheter
was positioned under fluoroscopic guidance with the
loop on the edge of the annulus from the 30 degree right
anterior oblique projection and the 50 degree left
anterior oblique projection to show the plane of the loop
at a 90 degree angle. Atrial electrograms were recorded
with the 10 paired electrodes from the right atrium and,
from the coronary sinus for the left atrial electrogram
during atrial fibrillation. Bipolar atrial electrograms and
surface leads were amplified with a physiologic recorder
(Nihon Koden, Tokyo, Japan). Filtered (30 to 600 Hz)
intra-atrial data were continuously recorded before,
during, and after the infusion of pilsicainide.

Pilsicainide infusion
Pilsicainide, a class IC antiarrhythmic agents, was
administered intravenously 0.1 mg/kg/min for 10 min
through an infusion pump (total dosage: 1 mg/kg) until
sinus rhythm was restored or the total dosage was
infused.

intra-atrial potentials were measured at 11 right atrial
sites, (10 from the Halo catheter positioned at the
tricuspid annulus and from the high right atrium) and
at a distal pair of electrodes at the coronary sinus at 1minute intervals. Measurements of the intervals and
widths between intra-atrial potentials were obtained
every minute until sinus rhythm was restored or until
15 minutes after the completion of the infusion of the
total dose of pilsicainide. Measurements of atrial cycle
length and width of atrial electrograms were made
manually at a paper speed of 100mm/s to an estimated
precision of 3 ms by two physicians. Actual data were
taken as an average of data measured by two physicians.

Definitions
1) AF interval: the mean of the intra-atrial intervals,
which is the beat to beat changes from the 12 atrial
sites.
2) AF 1 (the dispersion of the interval of atrial
fibrillation): the mean of the standard deviation of
the intra-atrial intervals among different atrial sites.
3) AF 2 (the dispersion of the interval of atrial
fibrillation): the mean of the difference between the
maximal and minimal atrial AF intervals among
different atrial sites.
4) AF width: the mean width of the intra-atrial
potentials, which is the beat to beat changes from
the 12 atrial sites.
5) AF width dispersion 1: the mean width of the
standard deviation of the intra-atrial potentials
among different atrial sites.
6) AF width dispersion 2: the mean of the difference
between the maximal and minimal atrial AF width
among different atrial sites.

Statistics
The differences in variables between two groups
were determined by a paired or nonpaired t test. The
differences in variables among groups and repeated
measurements within groups were investigated by
ANOVA. Probability levels of less than 0.05 were
considered statistically significant. All data are
presented as mean ± standard deviation.

Results
Measurements
During atrial fibrillation, 50 consecutive intervals
between the intra-atrial potentials and the width of the
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Spontaneous atrial fibrillation was terminated by
infusion of pilsicainide during the electrophysiologic
study in 6 of 11 patients (responders). Pilsicainide failed
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to induce a conversion to sinus rhythm in 5 patients
(non-responders). There were no significant differences
between groups in mean age, sex or echocardiographic
parameters (Table 1). In responders, atrial fibrillation
was terminated 5 to 10 minutes (means 9 minutes) after
the start of pilsicainide infusion. The AF interval
increased significantly in both responders (from 147 ±
28 ms on control to 224 ± 34 ms immediately before
termination) and non-responders (from 132 ± 41 ms on
control to 206 ± 20 ms on the completion of the infusion
of the total dose of pilsicainide). There was no
significant difference in the pilsicainide - induced
prolongation of the AF interval between groups
(responders: 71 ± 25 ms; non-responders: 87 ± 41 ms).
The AF interval increased during pilsicainide infusion
in both groups (Fig.1A). The AF interval just prior to
termination of atrial fibrillation was significantly greater
than those of previous AF interval in both groups. Figure
1B shows AF interval during the last 6 cycles just before
termination (0) of atrial fibrillation in responders and
on the completion of the infusion of the total dose of
pilsicainide (0) in non-responders. The AF interval just
prior to termination of atrial fibrillation was
significantly greater than those of previous AF interval
in responders, but not in non-responders (P<0.05 by
ANOVA). The baseline AF dispersion was similar in
both groups (responders: 11 ± 2 ms; non-responders:
10 ± 9 ms). Pilsicainide significantly increased the AF
dispersion in non-responders compared with responders
(non-responders 19 ± 6 ms vs responders 9 ± 3 ms; p
<0.05). The ratio of the AF dispersion to the AF interval
significantly decreased in responders (7.2 ± 1.2 on

control to 3.9 ± 1.7 immediately before termination;
p=0.0076), but no significantly different in nonresponders (from 8.8 ± 8.2 on control to 11.0 ± 4.2 on
the completion of the infusion of the total dosage of
pilsicainide). The pilsicainide - induced changes in the
AF dispersion were observed before the termination of
atrial fibrillation, which occurred at the minimal AF
dispersion (Fig. 2A). Figure 2B shows AF dispersion
during the last 6 cycles just before termination (0) of
atrial fibrillation in responders and on the completion
of the infusion of the total dose of pilsicainide (0) in
non-responders. The AF dispersion alternately increased
and decreased at all atrial potentials just prior to
termination in responders, but not in non-responders.
AF dispersion at 8 minutes after infusion of pilsicainide
in non-responder were apt to increase than base line (P
<0.05 by ANOVA). The AF interval just prior to
termination was greater than the interval at the
beginning of AF in responders and increased suddenly
just before conversion to sinus rhythm in 5 out of 6
cases in responders (Fig.3). The dispersion of AF
interval alternately increased and decreased just prior
to termination. Atrial fibrillation was terminated at the
relatively lower rate of AF dispersion. The AF widths
just prior to termination increased when compared with
those observed at the beginning of atrial fibrillation (Fig.
4). The AF width dispersion 1 and the AF width
dispersion 2 alternately increased and decreased at all
atrial potentials just prior to termination. Figure 5
illustrates a representative example of the
electrophysiologic presentation of termination of atrial
fibrillation. Upper panel demonstrates the change of

Table 1. Study Population
No. of pts.
Age (yrs)
Men/Women
Disease (No. of pts.)
SSS
Paroxysmal AF
WPW
AVNRT
Wchocardiogram
LA (mm)
LVDd (mm)
EF (%)
LA thrombus

responder
6
64 ± 22
5/1

non-responder
5
65 ± 8
2/3

P value
NS
NS
NS

2
4
0
0

2
2
0
1

NS
NS
NS
NS

37 ± 10
44 ± 10
80 ± 8
2

42 ± 4
46 ± 4
88 ± 1
2

NS
NS
NS
NS

pts: patients; AF: afrial fibrillation; AVNRT: atrioventricular nodal reentrant tachycardia; WPW: Wolf Parkinson White syndrome; LA: left
atrium; LVDd: dimmension of left ventricle (diastolic phase); EF: ejection fraction
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(A)

(B)

Figure 1. Beat-to-beat changes in the intra-atrial interval of atrial fibrillation during infusion of pilsicainide in the individual
patients (A). AF interval during the last 6 cycles just before termination (0) of atrial fibrillation in responders and on the
completion of the infusion of the tlotal dosage of pilsicainide (0) in non-responders. The AF interval just prior to termination of
atrial fibrillation was significantly greater than those of previous AF interval in both groups(B).

(A)

(B)

Figure 2. Beat-to-beat changes in the dispersion of the intra-atrial interval of atrial fibrillation during infusion of pilsicainide
in the individual patients (A). AF dispersion during the last 6 cycles just before termination (0) of atrial fibrillation in responders
and on the completion of the infusion of the tlotal dose of pilsicainide (0) in non-responders. The AF dispersion decreased at all
atrial potentials just prior to termination in responders, but not in non-responders (B).

90

October 1999

J HK Coll Cardiol, Vol 7

MECHANISM OF CONVERSION OF ATRIAL FIBRILLATION

Figure 3. The time course of beat-to-beat changes in the intra-atrial interval and dispersion during termination of atrial
fibrillation by pilsicainide in responders.

Figure 4. The time course of beat-to-beat changes in the width of intra-atrial potentials and dispersion during termination of
atrial fibrillation by pilsicainide in responders.
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Figure 5. Intracardiac electrocardiogram
recorded during termination of atrial fibrillation
by infusion of pilsicainide in representative
responders.

atrial electrograms from the quite chaotic pattern as type
III atrial fibrillation advocated by Wells et al. 6 to
discreate pattern separated by an isoelectric baseline as
type I atrial fibrillation and the prolongation of AF
interval just prior to termination of atrial fibrillation.
Lower panel shows another example of the termination
of atrial fibrillation. Increase of atrial potential at
anterior to lateral right atrium is observed just before
termination of atrial fibrillation.

Discussion
One explanation of the mechanism of termination
of atrial fibrillation is the circulating wavelet
hypothesis,7 which proposes that wavelets may fuse until
only one wavelet is left to circulate or that there is a
conduction block of all wavelets. Atrial fibrillation is
not related to an anatomical obstacle, that is, the
establishment of circus movement during atrial
fibrillation does not require a fully excitable gap. 8
Wavefronts associated with atrial fibrillation are
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believed to proceed along the pathway that restores the
refractory period. The cycle length of the circus
movement equals the interval of circuit divided by the
conduction velocity. In the circuit without excitable gap,
because the ratio of the interval of circuit to the
conduction velocity is equivalent to the refractory
period, the cycle length of the circus movement equals
the refractory period.9 Thus the refractory period result
in the establishment of circus movement during atrial
fibrillation. We measured the intervals of local intraatrial potentials instead of the refractory period, because
most studies investigating termination of atrial
fibrillation in animals10-12 and humans13-16 have found
that the atrial rate decreases before termination of atrial
fibrillation. Allessie et al. 12 reported that the atrial
waveform became "coarser" prior to termination,
suggesting that fusion was responsible for termination
of atrial fibrillation. Wang et al.16 reported that atrial
fibrillation could be terminated by increasing the
wavelength to the point at which the atrial fibrillation
could no longer sustain itself. They also suggested that
termination of atrial fibrillation may occur via fusion
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of wavelets. However, Sih et al.17 reported that the atrial
rate increased prior to termination in 3 of 15 episodes,
all 3 episodes terminated spontaneously. Thus, two types
of alterations in the atrial rate have been observed prior
to the cessation of atrial fibrillation. We hypothesize
that termination of atrial fibrillation associated with a
decreasing atrial rate and termination associated with
an increasing atrial rate before conversion to sinus
rhythm involve different mechanisms. The circulating
wavelet hypothesis of fibrillation suggests that
fibrillation may terminate via one of two different
mechanisms: the fusion of wavelets until only one
wavelet is left to circulate or blockade of all wavelets.7
Pilsicainide is a developed antiarrhythmic drug
in Japan which belongs to the class 1C antiarrhythmic
drugs. 18-19 Hattori et al. proposed that pilsicainide
belongs to the class 1C antiarrhythmic drugs
characterized by slow kinetics with respect to blocking
of the sodium channel.20 Terazawa et al. presented that
pilsicainide did not prolong the effective refractory
periods of the atrium and ventricle, and stated that
prolongation of conduction time without any alteration
of refractoriness may suggest class 1C antiarrhythmic
activity of this drug at therapeutic serum
concentrations. 21 Hattori et al. have shown that
pilsicainide has only minor effects on rabbit sinoatrial
node activity and on Ca2+ -mediated slow action
potentials of guinea-pig papillary muscles. 19 They
conclude that pilsicainide is a selective sodium channel
blocker. In the present study, termination of atrial
fibrillation may be induced by pilsicainide, a class 1C
antiarrhythmic drug that slows conduction. Class 1C
antiarrhythmic agents have been shown to be effective
in the management of atrial fibrillation. 22-25 The
mechanism of action of class 1C agents is an increase
in atrial refractoriness. 24 The intervals of the atrial
potentials increased after administration of pilsicainide,
that is, the atrial rate was decreased in the present study.
The atrial rate was significantly decreased in patients
in whom atrial fibrillation was successfully terminated
compared with those in whom atrial fibrillation was not
terminated. The atrial rate showed a sudden decrease
just before conversion to sinus rhythm in responders.
We measured the dispersion of the intervals of atrial
potentials (the standard deviation of the atrial interval
and the difference between the maximal and minimal
AF intervals) as an indicator of synchronization among
atrial recording sites. The present results suggest that
synchronizations of AF interval at all recording sites
was involved in the drug-induced termination of atrial
fibrillation. Type III atrial fibrillation has been changed
type I atrial fibrillation may indicate that complex

J HK Coll Cardiol, Vol 7

circuits fuse with simple circuit. Pilsicainide induced
significant changes in the atrial rate and the dispersion
prior to termination suggesting fusion of wavelets was
responsible for termination of atrial fibrillation. The
spontaneous termination of atrial fibrillation observed
by Sih et al. 17 may have been induced by the
simultaneous blockade of all wavelets because of the
absence of synchronization. Spontaneous termination
of atrial fibrilation is sometimes associated with a
decreasing atrial rate before termination.14 We propose
that these phenomena are related to different
mechanisms and in this respect we differ with Sih et
al., 16 who suggested that the mechanism of
antiarrhythmic drug-induced termination could be
differed from that of spontaneous termination. They
suggested that drug-induced termination may be due to
the simultaneous blockade of all wavelets and that
spontaneous termination may be due to the fusion
mechanism. The duration of atrial fibrillation was less
than 30 minutes in subjects with spontaneous
termination in the study by Sih et al, which may not be
long enough to establish a stable circuit for atrial
fibrillation. Prolongation of the interval and changes in
the dispersion of atrial fibrillation were also observed
in non-responders in the present study. Although
Boahene et al. have suggested that slowing of the atrial
rate by antiarrhythmic drugs is an important factor in
termination of atrial fibrillation,15 a decrease in the atrial
rate may not be sufficient to induce termination.16 Sih
et al. reported that the degree of synchrony of activity
among intra-atrial recording sites also failed to predict
termination of fibrillation. 16 The AF width of
intracardiac potentials may be inversely correlated with
the focal conduction velocity. A wide intracardiac
potential causes the wavefront passing through the
bipolar electrodes more slowly. Prolongation of the AF
width before termination of AF may indicate the slowing
of fibrillating activity in the focal atrium. Furthermore,
alternating beat-to-beat changes in the AF width
dispersion just before conversion suggested that the
conduction velocity was unstable in both atria. Thus,
successful termination of atrial fibrillation required a
sudden prolongation in the refractory period without
any change in the dispersion of refractory period in both
atria and a decreased conduction velocity in association
with the alternating changes in the each atria.

Study Limitation
A limitation of the present study is that only
twelve atrial electrocardiograms (11 for right atrium
and one for left atrium) were used in this study.
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Although we used the decapolar coronary sinus catheter
recording for left atrium, in fact, only one atrial
electrocardiogram from the decapolar coronary sinus
catheter was used for the analysis in this study. If all
five bipolar electro-cardiograms from the decapolar
coronary sinus catheter and another 20 pole halo catheter
along the crista terminalis would be used, further
detailed results might be obtained. The atrial rate
decreased and the dispersion of the cycle length of intraatrial potentials showed alternating increases and
decreases prior to termination even in the nonresponders. Class 1C antiarrhythmic agents slow
intracardiac conduction, prolong the refractory
period,24,26 and reduce regional heterogeneity in the
refractory period and in wavelengths. 17 Thus, the
slowing of the atrial rate and the change in the dispersion
of the atrial cycle length may have been merely the
effects of pilsicainide. The present results suggest that
patients in whom pilsicainide fails to terminate atrial
fibrillation may still achieve termination of fibrillation.
Thus, the presence of prolongation of the atrial interval
(slowing of the atrial rate) and decreasing the dispersion
at suitable time were required for the termination of
atrial fibrillation.
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